Artivion (NYSE:AORT) Trading Down 4.3% – What’s Next?

Artivion, Inc. (NYSE:AORT) shares traded down 4.3% on Thursday . The company traded as low as $24.06 and last traded at $23.9420. 96,287 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 598,663 shares. The stock had previously closed at $25.02.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AORT. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday, June 1st. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings lowered shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Artivion in a report on Monday, July 20th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Artivion Trading Down 4.8%

The business has a fifty day moving average price of $26.32 and a 200 day moving average price of $28.49. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company has a market capitalization of $1.16 billion, a PE ratio of -340.37 and a beta of 1.25.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The company had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Analysts expect that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Andrew M. Green sold 11,480 shares of Artivion stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $24.97, for a total transaction of $286,655.60. Following the sale, the senior vice president directly owned 40,160 shares of the company’s stock, valued at approximately $1,002,795.20. The trade was a 22.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 977 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the transaction, the senior vice president directly owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 90,460 shares of company stock valued at $2,557,366. Corporate insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AORT. BlackRock Inc. bought a new position in Artivion in the 2nd quarter worth approximately $149,965,000. Fred Alger Management LLC grew its position in Artivion by 4.2% in the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after buying an additional 55,322 shares during the last quarter. Conestoga Capital Advisors LLC acquired a new stake in shares of Artivion during the first quarter worth $43,044,000. Summit Partners Public Asset Management LLC purchased a new stake in Artivion during the fourth quarter valued at about $39,401,000. Finally, Dimensional Fund Advisors LP boosted its stake in Artivion by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,027,575 shares of the company’s stock worth $37,626,000 after purchasing an additional 46,738 shares during the period. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company’s portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.

Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.